– UK, Reading – Northern Venture Trust PLC (LON: NVT) announced the appointment of John Milad to its Board as a Non-Executive Director, bringing over 25 years of experience as an executive leader, board member, venture capital investor, and investment banker focussed on the life sciences and medical technology sectors.
John Milad will also join the audit, nomination, and management engagement committees.
About John E Milad
John Milad is currently the CEO of ERS Genomics, a licenser of the Nobel Prize-winning CRISPR/Cas9 gene editing technology.
Previously, John was co-founder and CEO of Quanta Dialysis Technologies, leading the development and commercial launch of a portable hemodialysis system. Before this, he served as CFO of Nitec Pharma, transitioning the company from the development to the commercial stage.
John Milad is also an experienced venture investor, with previous roles as Partner and co-head of Healthcare Ventures at Downing LLP and Investment Director at NBGI Ventures. Before that, he worked at Atlas Venture and Kirkland Investors.
John Milad currently serves as a Trustee on the Board of Kidney Research UK and is a business mentor at the Royal Academy of Engineering’s accelerator program.
For more: https://nvm.co.uk/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.